Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva: We Have 16 Biosimilars In The Pipeline, Our Aim Is 20

Firm Says It Has ‘Good Manufacturing’ But Will Also Continue Partnership Model

Executive Summary

A year into the job, Teva’s CEO Richard Francis returned to the J.P. Morgan Annual Healthcare Conference to discuss future investment in biosimilars and the importance of Teva’s long-acting injectable programs.

You may also be interested in...

Teva Returns To Growth For First Time In Six Years

The company also announced plans to divest its active pharmaceutical ingredients (API) business as part of its ‘Pivot to Growth’ strategy.

Adalimumab Uptake Set For A Boost As CVS Drops Humira From Formularies

US adalimumab biosimilars could soon see increased uptake after CVS Caremark announced plans to remove the Humira brand from its major national formularies entirely, in favor of biosimilars.

Teva Gets Investment From Royalty On Olanzapine LAI

Teva has announced a new investment from Royalty Pharma in its long-acting injectable formulation of olanzapine that is being developed for the US market with partner MedinCell.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts